ERRATUM

Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

J. Bart Rose, MD, MAS¹, Flavio G. Rocha, MD¹, Adnan Alseidi, MD¹, Thomas Biehl, MD¹, Ravi Moonka, MD¹, John A. Ryan, MD¹, Bruce Lin, MD², Vincent Picozzi, MD², and Scott Helton, MD¹

¹Section of General, Thoracic and Vascular Surgery, Department of Surgery, Virginia Mason Medical Center, Seattle, WA;

²Section of Medical Oncology, Department of Medicine, Virginia Mason Medical Center, Seattle, WA

ERRATUM TO: ANN SURG ONCOL DOI 10.1245/S10434-014-3486-Z

An error occurred in the Methods section, which is corrected here. The first sentence in the second paragraph, under the heading “Neoadjuvant Chemotherapy Regimen,” should read:

Eligible patients were started on an eight-cycle course of 1,000 mg/m² of gemcitabine and **40** mg/m²

of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels.

The sentence as originally published, “Eligible patients were started on an eight-cycle course of 1,000 mg/m² of gemcitabine and 80 mg/m² of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels,” is incorrect.

The online version of the original article can be found under doi:[10.1245/s10434-014-3486-z](https://doi.org/10.1245/s10434-014-3486-z).

© Society of Surgical Oncology 2014

Published Online: 17 March 2014

J. B. Rose, MD, MAS
e-mail: bart.rose@vmmc.org